Roche Holding Co. (ROG.VX) is preparing a new offer for Genentech Inc. (DNA), in which Roche already owns a 56% stake, The Financial Times reports Friday, without citing sources. The bid is expected to be about $95 a share, and could go before Genentech's board before the release of Roche's year-end figures, due in February. The bid would require debt financing of up to $35 billion. The FT says Roche's strategic target is Avastin, Genetech's colorectal cancer treatment, for which key trial results are to be published this summer. Roche is being advised by Greenhill, while Genentech has hired Goldman Sachs. Roche declined to comment to the FT.

Full story at http://www.ft.com/cms/s/0/15e54640-de7f-11dd-9464-000077b07658.html?nclick_check=1

-Dow Jones Newswires, 201-938-5500